Graybill Bartz & Assoc Ltd. continued to hold its stake in Eli Lilly and Company (NYSE:LLY) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,753 shares of the company’s stock at the end of the 2nd quarter. Graybill Bartz & Assoc Ltd.’s holdings in Eli Lilly and were worth $227,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the business. Vanguard Group Inc. lifted its stake in Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after acquiring an additional 2,181,701 shares during the last quarter. BlackRock Inc. lifted its stake in Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after acquiring an additional 59,978,664 shares during the last quarter. State Street Corp lifted its stake in Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock valued at $3,563,230,000 after acquiring an additional 651,424 shares during the last quarter. Geode Capital Management LLC lifted its stake in Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock valued at $764,597,000 after acquiring an additional 708,597 shares during the last quarter. Finally, Janus Capital Management LLC lifted its stake in Eli Lilly and by 2.8% in the first quarter. Janus Capital Management LLC now owns 8,723,692 shares of the company’s stock valued at $733,731,000 after acquiring an additional 237,619 shares during the last quarter. Hedge funds and other institutional investors own 75.53% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This report was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/graybill-bartz-assoc-ltd-has-227000-stake-in-eli-lilly-and-company-lly/1633714.html.

A number of brokerages have commented on LLY. Cowen and Company reiterated a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a research note on Wednesday, October 4th. Barclays PLC increased their price target on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a research note on Friday. BMO Capital Markets reiterated a “sell” rating and issued a $73.00 price target on shares of Eli Lilly and in a research note on Friday, August 4th. Piper Jaffray Companies reiterated a “buy” rating and issued a $105.00 price target on shares of Eli Lilly and in a research note on Friday. Finally, Morgan Stanley set a $86.00 price target on shares of Eli Lilly and and gave the company a “hold” rating in a research note on Friday, October 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $88.97.

In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares of the company’s stock, valued at $10,307,254,924.47. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last ninety days, insiders have sold 990,000 shares of company stock worth $82,949,650. Insiders own 0.20% of the company’s stock.

Shares of Eli Lilly and Company (NYSE:LLY) opened at 86.55 on Monday. The firm has a 50-day moving average of $83.56 and a 200 day moving average of $82.19. The firm has a market cap of $91.31 billion, a PE ratio of 37.45 and a beta of 0.34. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $89.09.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.86 earnings per share. Equities research analysts predict that Eli Lilly and Company will post $4.16 EPS for the current fiscal year.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.